Australia markets open in 35 minutes
  • ALL ORDS

    7,426.60
    +76.00 (+1.03%)
     
  • AUD/USD

    0.6969
    +0.0009 (+0.13%)
     
  • ASX 200

    7,182.70
    +70.20 (+0.99%)
     
  • OIL

    108.67
    -0.92 (-0.84%)
     
  • GOLD

    1,814.80
    -1.10 (-0.06%)
     
  • BTC-AUD

    41,662.84
    -2,367.93 (-5.38%)
     
  • CMC Crypto 200

    650.57
    -20.11 (-3.00%)
     

What This FDA News Could Mean for AbbVie's Stock

·4-min read
What This FDA News Could Mean for AbbVie's Stock
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Earlier this month, AbbVie (NYSE: ABBV) completed its application to the U.S. Food and Drug Administration (FDA) for Rinvoq to treat adults with a back arthritis (known as non-radiographic axial spondyloarthritis) who previously tried nonsteroidal anti-inflammatory drugs (NSAIDs) but did not benefit. If eventually approved by the FDA, this would be the fourth approved indication in the U.S. for Rinvoq. Let's take a look at Rinvoq's efficacy in treating patients with this form of back arthritis and the sales potential of the indication for pharma stock AbbVie.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting